FABRICE YVES NDJANA LESSOMO

Dr. FABRICE YVES NDJANA LESSOMO


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
FLFABRICE YVES NDJANA LESSOMO
FABRICE YVES NDJANA LESSOMO
OMOscar Onayi Mandizadza
Oscar Onayi Mandizadza
CMChishimba Mukuka
Chishimba Mukuka
ZWZhi-Quan Wang
Zhi-Quan Wang
Newly approved cancer drugs called ICIs have shown remarkable success in improving patient survival rates, but they also have the potential for inflammatory and immune-related side effects, including those affecting the cardiovascular system. Research has been conducted to understand the development of these toxicities and identify risk factors. This review focuses on the characteristics of ICI-induced cardiotoxicity and discusses the reported risk factors. It is important for cardio-oncologists to understand the basic concepts of these drugs to better understand how cardiotoxicities occur. It might be hard to find reports, where all patients treated with ICIs had developed cardiac toxicity, because there could be other existing and variable factors that influence the likelihood or risk of developing cardiotoxicity during treatment. Various clinical parameters have been explored as potential risk factors, and further investigation is needed through large-scale studies.